ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript

PresentationGood day, and thank you for standing by. Welcome to the ORIC Pharma Update Conference Call. [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Dominic Piscitelli. Please go ahead, sir.Dominic PiscitelliChief Financial Officer Welcome to the ORIC Pharmaceuticals rinzimetostat dose optimization data update call. Earlier today, we issued a press release highlighting new clinical data and details f ...